

Title (en)

ANTI-TRANSTHYRETIN ANTIBODIES AND METHODS OF USE THEREOF

Title (de)

ANTI-TRANSTHYRETIN-ANTIKÖRPER UND VERFAHREN ZUR VERWENDUNG DAVON

Title (fr)

ANTICORPS ANTI-TRANSTHYRÉTINE ET MÉTHODES D'UTILISATION ASSOCIÉES

Publication

**EP 4237005 A1 20230906 (EN)**

Application

**EP 21887569 A 20211028**

Priority

- US 202063106853 P 20201028
- US 202063106855 P 20201028
- US 202063122720 P 20201208
- US 2021057150 W 20211028

Abstract (en)

[origin: WO2022094152A1] Provided herein are methods and compositions for detecting, reducing, and inhibiting misfolded transthyretin protein.

IPC 8 full level

**A61K 39/395** (2006.01); **A61P 25/00** (2006.01); **A61P 25/28** (2006.01); **C07K 16/18** (2006.01)

CPC (source: EP US)

**A61P 9/00** (2017.12 - US); **A61P 25/00** (2017.12 - EP); **A61P 25/02** (2017.12 - US); **A61P 25/28** (2017.12 - EP); **C07K 16/18** (2013.01 - EP US);  
**A61K 2039/505** (2013.01 - US); **A61K 2039/54** (2013.01 - EP); **A61K 2039/545** (2013.01 - EP US); **C07K 2317/24** (2013.01 - EP);  
**C07K 2317/34** (2013.01 - EP); **C07K 2317/70** (2013.01 - EP)

Citation (search report)

See references of WO 2022094152A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

Designated validation state (EPC)

KH MA MD TN

DOCDB simple family (publication)

**WO 2022094152 A1 20220505**; EP 4237005 A1 20230906; JP 2023548005 A 20231115; US 2023391859 A1 20231207

DOCDB simple family (application)

**US 2021057150 W 20211028**; EP 21887569 A 20211028; JP 2023521103 A 20211028; US 202118033568 A 20211028